Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: betty moyers who wrote (19426)	3/9/1999 8:15:00 AM
From: Frostman	Respond to of 23519

Here are two takes from Briefing.com yesterday as things developed: <<11:55 ET VIVUS Inc (VVUS) 3 1/8 +15/16 (+43%) --Correction-- Vivus shares being lifted on news company has been issued a patent for its female sexual disfunction treatment. (Press Release) 11:22 ET VIVUS Inc (VVUS) 2 7/8 +11/16 (+31%): Heavily-shorted developer of erectile dysfunction treatment products has received notification that the license necessary for the launch of MUSE in Germany has been granted. This license triggers a $2 million milestone payment to VIVUS from ASTRA. Volume 860K >> Perhaps if the right pugwump stumbles out of his or her cave this week and sees its shadow, Vivus may get an upgrade or coverage initiated.